Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
Policy Medicare Reimbursement

US Medicare Agency Ends New Technology Add-On Payments For Some Devices, But May Grant It For Others In 2021

  • News

Executive Summary

The US Medicare agency will end three new technology add-on payments for devices in 2021 but continue payments for a T2 bacteria panel, and is considering the funding for other assays and devices next year.

You may also be interested in...



CMS Cements In Place Permanent Telehealth Reimbursements In Final Physician Pay Rule

Beneficiaries in nursing homes and in rural areas will benefit from a telehealth expansion in the final CMS physician fee schedule rule.

GAO/NAS Report On AI In Health Care Critical Of FDA Slowness On SaMD Rulemaking

A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.

COVID-19: CMS Allowing Hospital-Level Payments For Home-Based Care

The US Medicare agency is letting ambulatory surgical centers and patient homes be reimbursed as in-patient hospitals for patient care purposes during the pandemic.

Table

View full table

Topics

Tags:
Policy Medicare Reimbursement
UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By